Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations

Hashita,Tadahiro; Katsuyama,Yoshihiko; Nakamura,Katsunori; Momose,Yasuyuki; Komatsu,Daisuke; Koide,Naohiko; Miyagawa,Shinichi; Nakamura,Tomonori; Yamamoto,Koujirou; Ohmori,Shigeru

doi:10.3892/ol.2012.779

September 2012 Volume 4 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September 2012 Volume 4 Issue 3

Full Size Image

Article

Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations

Authors:
- Tadahiro Hashita
- Yoshihiko Katsuyama
- Katsunori Nakamura
- Yasuyuki Momose
- Daisuke Komatsu
- Naohiko Koide
- Shinichi Miyagawa
- Tomonori Nakamura
- Koujirou Yamamoto
- Shigeru Ohmori
View Affiliations / Copyright

Affiliations: Department of Pharmacy, Shinshu University Hospital, Matsumoto, Japan, Department of Surgery, Shinshu University Hospital, Matsumoto, Japan, Department of Clinical Pharmacology, Gunma University Graduate School of Medicine, Maebashi, Japan
Pages: 501-504
|
Published online on: June 28, 2012

https://doi.org/10.3892/ol.2012.779
Expand metrics +

Abstract

In this study we report the pharmacokinetics and severe adverse effects of sunitinib in a woman with a gastrointestinal stromal tumor (GIST). A 60-year-old woman with small intestinal GIST developed severe thrombocytopenia (1.7x104/µl) following 1 week of treatment with sunitinib at 50 mg/day. Although the dose of sunitinib was reduced to 25 mg/day, platelet levels remained low. On day 7, the trough concentration of sunitinib plus SU12662 was 46.1 ng/ml and the area under the curve (AUC) was 1,393.0 ng·h/l. The dose was again reduced to 12.5 mg/day. However, the day after resumption of treatment, the patient developed symptoms of left heart failure due to myocardosis caused by sunitinib. Sunitinib has been reported to inhibit platelet-derived growth factor receptor (PDGFR) phosphorylation at concentrations over the range of 50-100 ng/ml (sunitinib plus SU12662) in vivo. In this case, the plasma concentration was sufficient to inhibit PDGFR at 25 or 50 mg/day. However, thrombocytopenia appeared at both dosages. Although the results in this case did not suggest a correlation between thrombocytopenia and plasma concentration, the degree of thrombocytopenia was decreased by reduction of the dose. In conclusion, the findings reported here indicate that the plasma concentration of sunitinib plus SU12662 is an important indicator to reduce adverse effects.

View Figures

View References

1	Rubin BP: Gastrointestinal stromal tumours: an update. Histopathology. 48:83–96. 2006. View Article : Google Scholar : PubMed/NCBI
2	Hormick JL and Fletcher CD: The role of KIT in the management of patients with gastrointestinal stromal tumours. Hum Pathol. 38:679–687. 2007. View Article : Google Scholar : PubMed/NCBI
3	Debiec-Rychter M, Sciot R, Le Cesne A, et al: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 42:1093–1103. 2006. View Article : Google Scholar : PubMed/NCBI
4	Mendel DB, Laird AD, Xin X, et al: In vivo antitumour activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 9:327–337. 2003.
5	Murray LJ, Abrams TJ, Long KR, et al: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis. 20:757–766. 2003. View Article : Google Scholar : PubMed/NCBI
6	Chen M, Nafziger AN and Bertino JS Jr: Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. Drug Metab Dispos. 34:2079–2082. 2006. View Article : Google Scholar : PubMed/NCBI
7	Blanchet B, Saboureau C, Benichou AS, et al: Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma. Clin Chim Acta. 404:134–139. 2009. View Article : Google Scholar : PubMed/NCBI
8	Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD and Moltzer RJ: Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemther Pharmacol. 66:357–371. 2010. View Article : Google Scholar : PubMed/NCBI
9	Houk BE, Bello CL, Kang D and Amantea M: A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res. 15:2497–2506. 2009. View Article : Google Scholar : PubMed/NCBI
10	Nakazawa Y, Chisuwa H, Ikegami T, et al: Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in liver-related liver transplantation. Transplantation. 66:1089–1093. 1998. View Article : Google Scholar : PubMed/NCBI
11	Urata K, Kawasaki S, Matsunami H, et al: Calculation of child and adult standard liver volume for liver transplantation. Hepatology. 21:1317–1321. 1995.PubMed/NCBI
12	Kuehl P, Zhang J, Lin Y, et al: Sequence diversity in CYP3A promoters and characterization of the genetics basis of polymorphic CYP3A5 expression. Nat Genet. 27:383–391. 2001. View Article : Google Scholar
13	Saeki M, Saito Y, Nakamura T, et al: Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum Mutat. 21:6532003. View Article : Google Scholar : PubMed/NCBI
14	Balram C, Zhou Q, Cheung YB and Lee EJ: CYP3A53* and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol. 59:123–126. 2003.
15	Fukuen S, Fukuda T, Maune H, et al: Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A53 and 6, in a Japanese population. Pharmacogenetics. 12:331–334. 2002.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles